A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics

Pancreatic ductal adenocarcinoma (PDA) is the fourth leading cause of cancer-related deaths in the United States, and is projected to be second by 2025. It has the worst survival rate among all major cancers. Two pressing needs for extending life expectancy of affected individuals are the developmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Ocal, Ozhan, Pashkov, Victor, Kollipara, Rahul K., Zolghadri, Yalda, Cruz, Victoria H., Hale, Michael A., Heath, Blake R., Artyukhin, Alex B., Christie, Alana L., Tsoulfas, Pantelis, Lorens, James B., Swift, Galvin H., Brekken, Rolf A., Wilkie, Thomas M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Company of Biologists 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4610235/
https://www.ncbi.nlm.nih.gov/pubmed/26438693
http://dx.doi.org/10.1242/dmm.020933

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4610235/
https://www.ncbi.nlm.nih.gov/pubmed/26438693
http://dx.doi.org/10.1242/dmm.020933

Ejemplares similares